Search

Your search keyword '"Khamashta, Munther A"' showing total 397 results
Start Over Author "Khamashta, Munther A" Search Limiters Peer Reviewed
397 results on '"Khamashta, Munther A"'

2. Attainment of remission and low disease activity after treatment with belimumab in patients with systemic lupus erythematosus: a post-hoc analysis of pooled data from five randomised clinical trials

Author

Parodis, Ioannis, Lindblom, Julius, Levy, Roger A, Zen, Margherita, Cetrez, Nursen, Gomez, Alvaro, Oon, Shereen, Henning, Christine, Khamashta, Munther, Quasny, Holly A, Chauhan, Deven, Askanase, Anca, van Vollenhoven, Ronald, and Nikpour, Mandana

Published
2024
Full Text
View/download PDF

3. Survey on antiphospholipid syndrome diagnosis and antithrombotic treatment in patients with ischemic stroke, other brain ischemic injury, or arterial thromboembolism in other sites: communication from ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies

Author

Amoura, Zahir, Andrade, Danieli, Baccouche, Hela, Baldwin, Neil, Baysal, Mehmet, Belmont, H. Michael, Bertolaccini, M. Laura, Billett, Henny, Cervera, Ricard, Cohen, Hannah, Chandratheva, Arvind, Cotelli, Maria Sofia, Crowther, Mark, Devreese, Katrien, Dounaevskaia, Vera, Doyle, Andrew J., Barros Duran, Leandro Francisco, Engelbrecht, Sunelle, Efthymiou, Maria, Erkan, Doruk, Gatt, Alex, Gebhart, Johanna, Harkness, Kirsty, Hemelsoet, Dimitri, Hoirisch-Clapauch, Silvia, Inanc, Murat, Isenberg, David, Iturre, Maximiliano Villagra, Kalladka, Dheeraj, Kamphuisen, Pieter W., Kartsios, Charalampos, Khamashta, Munther, Kouides, Peter A., Levine, Steven R., Limper, Maarten, Luchtman-Jones, Lori, Maclean, Rhona, Mitchell, Christopher, Mittal, Prabal, Moll, Rachel, Molnar, Soledad, Moyer, Genevieve Claire, Muñoz Muñoz, Cándido, Murphy, Sean, Nwagha, Theresa, Orsi, Fernanda A., Pardos-Gea, José, Pengo, Vittorio, Prabu, Athiveeraramapandian, Rahman, Anisur, Roberts, Lara N., Ruiz-Irastorza, Guillermo, Sayar, Zara, Schulman, Sam, Sciascia, Savino, Siguret, Virginie, The, Lee-Suan, Tohodi-Esfahani, Ibrahim, Uthman, Imad, Vanhooren, Geert, Werring, David, Willis, Rohan, Yang, Chengde, Yee, Chee-Seng, Werring, David J., Devreese, Katrien M.J., and Isenberg, David A.

Published
2023
Full Text
View/download PDF

4. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study

Author

Pons-Estel, Guillermo, Giannakopoulos, Bill, Krilis, Steve, de Jesus, Guilherme, Levy, Roger, Signorelli, Flavio, Andrade, Danieli, Balbi, Gustavo, Clarke, Ann E., Skeith, Leslie, Fortin, Paul R., Ji, Lanlan, Zhang, Zhouli, Yang, Chengde, Shi, Hui, Zuily, Stephane, Wahl, Denis, Tektonidou, Maria G., Nalli, Cecilia, Andreoli, Laura, Tincani, Angela, Chighizola, Cecilia B., Gerosa, Maria, Meroni, Pierluigi, Pengo, Vittorio, Cheng, Chunyan, Pazzola, Giulia, Sciascia, Savino, Foddai, Silvia, Radin, Massimo, Davis, Stacy, Amengual, Olga, Atsumi, Tatsuya, Uthman, Imad, Limper, Maarten, Groot, Philip de, Ruiz—Irastorza, Guillermo, Ugarte, Amaia, Rodriguez-Pinto, Ignasi, Cervera, Ricard, Pardos-Gea, Jose, Rodriguez Almaraz, Esther, Cuadrado, Maria Jose, Aguirre Zamorano, Maria Angeles, Lopez-Pedrera, Chary, Artim-Esen, Bahar, Inanc, Murat, Bertolaccini, Maria Laura, Cohen, Hannah, Efthymiou, Maria, Khamashta, Munther, Mackie, Ian, Sanna, Giovanni, Knight, Jason, Zuo, Yu, Petri, Michelle, Leaf, Rebecca K., Roubey, Robert, Ortel, Thomas, Gonzalez, Emilio, Willis, Rohan, Kello, Nina, Belmont, Michael, Levine, Steven, Rand, Jacob, Barbhaiya, Medha, Erkan, Doruk, Salmon, Jane, Lockshin, Michael, Duarte Garcia, Ali A., Branch, D. Ware, Gkrouzman, Elena, Ruiz-Irastorza, Guillermo, Belmont, H. Michael, Rodriguez-Almaraz, Esther, Petri, Michelle A., and Knight, Jason S.

Published
2023
Full Text
View/download PDF

5. Immunology of pregnancy and reproductive health in autoimmune rheumatic diseases. Update from the 11th International Conference on Reproduction, Pregnancy and Rheumatic Diseases

Author

Andreoli, Laura, Chighizola, Cecilia B., Iaccarino, Luca, Botta, Angela, Gerosa, Maria, Ramoni, Véronique, Tani, Chiara, Bermas, Bonnie, Brucato, Antonio, Buyon, Jill, Cetin, Irene, Chambers, Christina D., Clowse, Megan E.B., Costedoat-Chalumeau, Nathalie, Cutolo, Maurizio, De Carolis, Sara, Dolhain, Radboud, Fazzi, Elisa M., Förger, Frauke, Giles, Ian, Haase, Isabell, Khamashta, Munther, Levy, Roger A., Meroni, Pier Luigi, Mosca, Marta, Nelson-Piercy, Catherine, Raio, Luigi, Salmon, Jane, Villiger, Peter, Wahren-Herlenius, Marie, Wallenius, Marianne, Zanardini, Cristina, Shoenfeld, Yehuda, and Tincani, Angela

Published
2023
Full Text
View/download PDF

6. Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally

Author

Yee, Chee‐Seng, Gordon, Caroline, Isenberg, David A., Griffiths, Bridget, Teh, Lee‐Suan, Bruce, Ian N., Ahmad, Yasmeen, Rahman, Anisur, Prabu, Athiveeraramapandian, Akil, Mohammed, McHugh, Neil, Edwards, Christopher J., DʼCruz, David, Khamashta, Munther A., and Farewell, Vernon T.

Published
2022
Full Text
View/download PDF

8. Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications

Author

Bernatsky, Sasha, Ramsey‐Goldman, Rosalind, Urowitz, Murray B., Hanly, John G., Gordon, Caroline, Petri, Michelle A., Ginzler, Ellen M., Wallace, Daniel J., Bae, Sang‐Cheol, Romero‐Diaz, Juanita, Dooley, Mary Anne, Peschken, Christine A., Isenberg, David A., Rahman, Anisur, Manzi, Susan, Jacobsen, Søren, Lim, S. Sam, van Vollenhoven, Ronald, Nived, Ola, Kamen, Diane L., Aranow, Cynthia, Ruiz‐Irastorza, Guillermo, Sánchez‐Guerrero, Jorge, Gladman, Dafna D., Fortin, Paul R., Alarcón, Graciela S., Merrill, Joan T., Kalunian, Kenneth C., Ramos‐Casals, Manuel, Steinsson, Kristjan, Zoma, Asad, Askanase, Anca, Khamashta, Munther A., Bruce, Ian, Inanc, Murat, and Clarke, Ann E.

Published
2021
Full Text
View/download PDF

9. Lupus Nephritis Outcomes after Stopping Immunosuppression.

Author

Alenzi, Fahidah, Ateka-Barrutia, Oier, Ken Cheah, Chee, Khamashta, Munther, Sangle, Shirish R., and D'Cruz, David P.

Subjects
LUPUS nephritis, TERMINATION of treatment, MEDIAN (Mathematics), IMMUNOSUPPRESSION, PATIENTS' attitudes, DISEASE remission
Abstract

Background/Objectives: Immunosuppression (IS) is a standard therapy for lupus nephritis (LN). Data on the outcomes of patients with LN after the discontinuation of immunosuppression remain uncertain. This study aimed to evaluate the outcomes and results of patients with lupus nephritis (LN) who ceased immunosuppressive (IS) therapy. Methods: Records were obtained on the clinical and laboratory features of LN patients who were treated at our Lupus Unit. They included median values and ranges for various numerical variables such as patient age, disease duration, and treatment duration. Categorical variables such as gender, LN class, IS treatment type, and patient outcomes, which were categorized as either "stable" or "flare experienced", were presented as percentages and frequencies. A flare in LN was characterized by a two-fold increase in serum creatinine levels and a rise in proteinuria following the cessation of IS medication. Results: Outcomes were assessed for 45 patients with LN who ceased IS therapy after achieving remission. The patients' median age was 55 years (29–78). The median duration of treatment was 4 years (0.5–14). The LN histology distribution was class V = 24.4%, class IV = 17.8 %, class III = 17.8%, class III + IV = 15.6%, class III + V = 6.7%, class IV + V = 2.2%, and class II + IV and II = 2.2%. At the discontinuation of IS treatment, creatinine levels were elevated in 9/45 (20%) patients. Furthermore, 28.9% of patients relapsed after IS treatment discontinuation. Patients with anti-Smith antibodies (anti-Sm) were observed to have a higher occurrence of relapses, with six patients experiencing flare compared to four patients who remained stable (p = 0.03). Five (38.5%) of the patients with flares had high creatinine levels after IS discontinuation. Conclusions: Most of our patients maintained clinical remission and stable levels of LN parameters after IS treatment discontinuation. Those with a high serum creatinine level, ongoing proteinuria, depleted complement levels, and the presence of anti-Sm antibodies were more likely to experience flares after the discontinuation of IS therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Anticoagulant and non-anticoagulant therapy in thrombotic antiphospholipid syndrome: old drugs and new treatment targets.

Author

Ruiz-Irastorza, Guillermo, Tektonidou, Maria G, and Khamashta, Munther

Subjects
HEMORRHAGE risk factors, THROMBOLYTIC therapy, THROMBOSIS risk factors, STATINS (Cardiovascular agents), B cells, COMPLEMENT (Immunology), ANTIPHOSPHOLIPID syndrome, ARTERIES, CELLULAR therapy, ANTICOAGULANTS, DRUG resistance, NEUROTRANSMITTERS, VENOUS thrombosis, MEDICAL protocols, INTERFERONS, ASPIRIN, TRANSFERASES, DRUGS, HYDROXYCHLOROQUINE, INTERNATIONAL normalized ratio, VITAMIN K, PHARMACODYNAMICS, CHEMICAL inhibitors, DISEASE complications
Abstract

In this review, we discuss the current evidence on classic and newer oral anticoagulant therapy, older drugs such as HCQ and statins, and new potential treatment targets in APS. Vitamin K antagonists (VKAs) remain the cornerstone treatment for thrombotic events in APS. In patients fulfilling criteria for definite APS presenting with a first venous thrombosis, treatment with VKAs with a target international normalized ratio (INR) 2.0–3.0 is recommended. In patients with arterial thrombosis, treatment with VKA with target INR 2.0–3.0 or 3.0–4.0 is recommended by recent guidelines, considering the individual's bleeding and thrombosis recurrence risk. A combination of VKAs and low-dose aspirin (75–100 mg/daily) may also be considered. According to available evidence direct oral anticoagulants should be avoided in patients with arterial thrombosis and/or those with triple aPL positivity. Adjunctive treatment with HCQ and/or statins can be considered, especially in anticoagulation treatment–refractory APS. Potential targeted treatments in APS include B-cell targeting, complement inhibition, mammalian target of rapamycin inhibition, IFN targeting, adenosine receptors agonists, CD38 targeting or chimeric antigen receptor T-cell therapy. The safety and efficacy of these treatment targets needs to be examined in well-designed randomized controlled trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria

Author

Barbhaiya, Medha, Zuily, Stephane, Ahmadzadeh, Yasaman, Amigo, Mary‐Carmen, Avcin, Tadej, Bertolaccini, Maria Laura, Branch, D. Ware, de Jesus, Guilherme, Devreese, Katrien M. J., Frances, Camille, Garcia, David, Guillemin, Francis, Levine, Steven R., Levy, Roger A., Lockshin, Michael D., Ortel, Thomas L., Seshan, Surya V., Tektonidou, Maria, Wahl, Denis, Willis, Rohan, Naden, Ray, Costenbader, Karen, Erkan, Doruk, Agmon‐Levin, Nancy, Aguilar, Cassyanne, Alba, Paula, Alpan, Oral, Ambrozic, Ales, Amoura, Zahir, Andrade, Danieli, Andrade, Luis, Appenzeller, Simone, Esen, Bahar Artim, Atsumi, Tatsuya, Berkun, Yackov, Cabral, Antonio, Canaud, Guillaume, Cervera, Ricard, Chen, Pojen, Chighizola, Cecilia, Cimaz, Rolando, Cohen, Hannah, Costedoat‐Chalumeau, Nathalie, Crowther, Mark, Cuadrado, Maria Jose, de Groot, Philip G., de Moerloose, Philippe, Derksen, Ronald, Diz‐Kucukkaya, Reyhan, Dörner, Thomas, Fortin, Paul, Giannakopoulos, Bill, Gómez‐Puerta, Jose A., Gonzalez, Emilio B., Inanc, Murat, Kenet, Gili, Khamashta, Munther, Kriegel, Martin, Krilis, Steven, Laskin, Carl, Massicotte, Patti, McCarty, Gale, Meroni, Pier Luigi, Mikdashi, Jamal, Myones, Barry, Pengo, Vittorio, Petri, Michelle, Roubey, Robert, Sammaritano, Lisa, Sanna, Giovanni, Sciascia, Savino, Signorelli, Flavio, Soybilgic, Arzu, Tincani, Angela, Woller, Scott, and Yelnik, Cécile

Published
2021
Full Text
View/download PDF

12. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial

Author

Cohen, Hannah, Hunt, Beverley J, Efthymiou, Maria, Arachchillage, Deepa R J, Mackie, Ian J, Clawson, Simon, Sylvestre, Yvonne, Machin, Samuel J, Bertolaccini, Maria L, Ruiz-Castellano, Maria, Muirhead, Nicola, Doré, Caroline J, Khamashta, Munther, and Isenberg, David A

Published
2016
Full Text
View/download PDF

13. Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil.

Author

Akthar, Mumina, Nair, Nisha, Carter, Lucy M., Vital, Edward M., Sutton, Emily, McHugh, Neil, Gordon, Patrick, Young-Min, Steven, Stevens, Robert, Prabu, Athiveer, Batley, Mike, Gendi, Nagui, Dasgupta, Bhaskar, Khamashta, Munther, Hewins, Peter, Stratton, Richard J., Chan, Antoni, De Lord, Denise, King, Jon, and Dubey, Shirish

Published
2023
Full Text
View/download PDF

17. Patient Care Pathways for Pregnancy in Rare and Complex Rheumatic Diseases: Results From an International Survey.

Author

Tani, Chiara, Zucchi, Dina, Bellis, Elisa, Talabi, Mehret Birru, Frise, Charlotte, de Jesús, Guilherme Ramires, Koksvik, Hege Svean, Lledó, Gema Maria, Mekinian, Arsène, Marinello, Diana, Palla, Ilaria, Mehta, Puja, Comet, Luis Sáez, Shaimaa, Shoela, Smeele, Hieronymus T. W., Talarico, Rosaria, Brucato, Antonio, Khamashta, Munther, Shoenfeld, Yehuda, and Tincani, Angela

Published
2023
Full Text
View/download PDF

18. Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil.

Author

Akhtar, Mumina, Nair, Nisha, Carter, Lucy M., Vital, Edward M., Sutton, Emily, McHugh, Neil, British Isles Lupus Assessment Group Biologics Register (BILAG BR) Consortium, Gordon, Patrick, Young-Min, Steven, Stevens, Robert, Prabu, Athiveer, Batley, Mike, Gendi, Nagui, Dasgupta, Bhaskar, Khamashta, Munther, Hewins, Peter, Stratton, Richard J., Chan, Antoni, De Lord, Denise, and King, Jon

Published
2023
Full Text
View/download PDF

20. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice.

Author

Schreiber, Karen, Frishman, Margreta, Russell, Mark D, Dey, Mrinalini, Flint, Julia, Allen, Alexander, Crossley, Amy, Gayed, Mary, Hodson, Kenneth, Khamashta, Munther, Moore, Louise, Panchal, Sonia, Piper, Madeleine, Reid, Clare, Saxby, Katherine, Senvar, Naz, Tosounidou, Sofia, van de Venne, Maud, Warburton, Louise, and Williams, David

Subjects
FETAL abnormalities -- Risk factors, RHEUMATOLOGY, MEDICAL protocols, ANTIRHEUMATIC agents, BREASTFEEDING, DRUG prescribing, PHYSICIAN practice patterns, FETAL abnormalities, HEALTH promotion
Abstract

The article presents guidelines on prescribing comorbidity medications used in rheumatology practice to pregnant and breastfeeding women from the British Society for Rheumatology. The objective is to update previous guidelines on prescribing for drug categories like pain management, anticoagulants and pulmonary vasodilators. It excludes the management of infertility or acute pain relief during labour.

Published
2023
Full Text
View/download PDF

21. Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.

Author

Russell, Mark D, Dey, Mrinalini, Flint, Julia, Davie, Philippa, Allen, Alexander, Crossley, Amy, Frishman, Margreta, Gayed, Mary, Hodson, Kenneth, Khamashta, Munther, Moore, Louise, Panchal, Sonia, Piper, Madeleine, Reid, Clare, Saxby, Katherine, Schreiber, Karen, Senvar, Naz, Tosounidou, Sofia, van de Venne, Maud, and Warburton, Louise

Subjects
ADRENOCORTICAL hormones, RHEUMATOLOGY, IMMUNOMODULATORS, MEDICAL protocols, ANTIRHEUMATIC agents, DRUG prescribing, BREASTFEEDING, DRUG-induced abnormalities, PREGNANCY complications, PHYSICIAN practice patterns, ANTIMALARIALS, PREGNANCY
Abstract

The article presents guidelines on prescribing immunomodulatory anti-rheumatic drugs and corticosteroids to pregnant and breastfeeding women from the British Society for Rheumatology. The objective is to update the previous guidelines and highlight medications that have to be stopped and avoided in the reproductive age group. It excludes the management of infertility or the indications for the drugs in rheumatic diseases in pregnancy.

Published
2023
Full Text
View/download PDF

22. Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice.

Author

Schreiber, Karen, Frishman, Margreta, Russell, Mark D, Dey, Mrinalini, Flint, Julia, Allen, Alexander, Crossley, Amy, Gayed, Mary, Hodson, Kenneth, Khamashta, Munther, Moore, Louise, Panchal, Sonia, Piper, Madeleine, Reid, Clare, Saxby, Katherine, Senvar, Naz, Tosounidou, Sofia, van de Venne, Maud, Warburton, Louise, and Williams, David

Subjects
DRUG therapy for rheumatism, MOTHERS, ANTIHYPERTENSIVE agents, DIPHOSPHONATES, RHEUMATOLOGY, NONSTEROIDAL anti-inflammatory agents, PREGNANT women, MEDICAL protocols, ANTIRHEUMATIC agents, PREGNANCY outcomes, BREASTFEEDING, DRUG prescribing, PLATELET aggregation inhibitors, PHYSICIAN practice patterns, IMMUNOSUPPRESSIVE agents, PAIN management
Abstract

The article presents guidelines on prescribing comorbidity medications used in rheumatology practice to pregnant and breastfeeding women from the British Society for Rheumatology. The objective is to update previous guidelines on prescribing for drug categories like pain management, anticoagulants and anti-hypertensives. It excludes the management of infertility or acute pain relief during labour.

Published
2023
Full Text
View/download PDF

23. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids.

Author

Russell, Mark D, Dey, Mrinalini, Flint, Julia, Davie, Philippa, Allen, Alexander, Crossley, Amy, Frishman, Margreta, Gayed, Mary, Hodson, Kenneth, Khamashta, Munther, Moore, Louise, Panchal, Sonia, Piper, Madeleine, Reid, Clare, Saxby, Katherine, Schreiber, Karen, Senvar, Naz, Tosounidou, Sofia, van de Venne, Maud, and Warburton, Louise

Subjects
PREVENTION of drug side effects, DRUG standards, ADRENOCORTICAL hormones, RHEUMATOLOGY, ANTIRHEUMATIC agents, PERINATAL death, MEDICAL protocols, DRUG prescribing, BREASTFEEDING, PREGNANCY complications, PHYSICIAN practice patterns, PREGNANCY
Abstract

The article presents guidelines on prescribing immunomodulatory anti-rheumatic drugs and corticosteroids to pregnant and breastfeeding women from the British Society for Rheumatology. Uncertainty over the use of the drugs in pregnancy and breastfeeding has led to the expansion of existing and novel disease-modifying antirheumatic drugs. The guideline excludes the management of infertility or indications in specific rheumatic diseases in pregnancy.

Published
2023
Full Text
View/download PDF

24. Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine.

Author

Reynolds, John A, Gayed, Mary, Khamashta, Munther A, Leone, Francesca, Toescu, Veronica, Bruce, Ian N, Giles, Ian, Teh, Lee-Suan, McHugh, Neil, Akil, Mohammed, Edwards, Christopher J, and Gordon, Caroline

Subjects
MOTHERS, AZATHIOPRINE, RETROSPECTIVE studies, ACQUISITION of data, PREGNANCY outcomes, LOW birth weight, INFECTION, BREASTFEEDING, RESEARCH funding, QUESTIONNAIRES, MEDICAL records, SYSTEMIC lupus erythematosus, HYDROXYCHLOROQUINE, LOGISTIC regression analysis, ODDS ratio, PREGNANCY
Abstract

Objectives HCQ and AZA are used to control disease activity and reduce risk of flare during pregnancy in patients with SLE. The aim of this study was to determine the outcomes of children born to mothers with SLE exposed to HCQ or AZA during pregnancy and breast-feeding. Methods Women attending UK specialist lupus clinics with children ≤17 years old, born after SLE diagnosis, were recruited to this retrospective study. Data were collected using questionnaires and from clinical record review. Factors associated with the outcomes of low birth weight and childhood infection were determined using multivariable mixed-effects logistic regression models. Results We analysed 284 live births of 199 mothers from 10 UK centres. The first pregnancies of 73.9% of mothers (147/199) were captured in the study; (60.4%) (150/248) and 31.1% (87/280) children were exposed to HCQ and AZA, respectively. There were no significant differences in the frequency of congenital malformations or intrauterine growth restriction between children exposed or not to HCQ or AZA. AZA use was increased in women with a history of hypertension or renal disease. Although AZA was associated with low birth weight in univariate models, there was no significant association in multivariable models. In adjusted models, exposure to AZA was associated with increased reports of childhood infection requiring hospital management [odds ratio 2.283 (1.003, 5.198), P  = 0.049]. Conclusions There were no significant negative outcomes in children exposed to HCQ in pregnancy. AZA use was associated with increased reporting of childhood infection, which warrants further study. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports.

Author

Petri, Michelle, Landy, Helain, Clowse, Megan E. B., Gemzoe, Kim, Khamashta, Munther, Kurtinecz, Milena, Levy, Roger A., Liu, Andrew, Marino, Rebecca, Meizlik, Paige, Pimenta, Jeanne M., Sumner, Kelsey, Tilson, Hugh, Connolly, Mary Beth, Wurst, Keele, Harris, Julia, Quasny, Holly, Juliao, Patricia, and Roth, David A.

Published
2023
Full Text
View/download PDF

26. The BILAG-2004 index is associated with development of new damage in SLE.

Author

Yee, Chee-Seng, Gordon, Caroline, Akil, Mohammed, Lanyon, Peter, Edwards, Christopher J, Isenberg, David A, Rahman, Anisur, Teh, Lee-Suan, Tosounidou, Sofia, Stevens, Robert, Prabu, Athiveeraramapandian, Griffiths, Bridget, McHugh, Neil, Bruce, Ian N, Ahmad, Yasmeen, Khamashta, Munther A, and Farewell, Vernon T

Subjects
SYSTEMIC lupus erythematosus diagnosis, RESEARCH, CONFIDENCE intervals, MORTALITY, DESCRIPTIVE statistics, RESEARCH funding, SYSTEMIC lupus erythematosus, LONGITUDINAL method
Abstract

Objective To determine whether BILAG-2004 index is associated with the development of damage in a cohort of SLE patients. Mortality and development of damage were examined. Methods This was a multicentre longitudinal study. Patients were recruited within 12 months of achieving fourth ACR classification criterion for SLE. Data were collected on disease activity, damage, SLE-specific drug exposure, cardiovascular risk factors, antiphospholipid syndrome status and death at every visit. This study ran from 1 January 2005 to 31 December 2017. Descriptive statistics were used to analyse mortality and development of new damage. Poisson regression was used to examine potential explanatory variables for development of new damage. Results A total of 273 SLE patients were recruited with total follow-up of 1767 patient-years (median 73.4 months). There were 6348 assessments with disease activity scores available for analysis. During follow-up, 13 deaths and 114 new damage items (in 83 patients) occurred. The incidence rate for development of damage was higher in the first 3 years before stabilizing at a lower rate. Overall rate for damage accrual was 61.1 per 1000 person-years (95% CI: 50.6, 73.8). Analysis showed that active disease scores according to BILAG-2004 index (systems scores of A or B, counts of systems with A and BILAG-2004 numerical score) were associated with development of new damage. Low disease activity (LDA) states [BILAG-2004 LDA and BILAG Systems Tally (BST) persistent LDA] were inversely associated with development of damage. Conclusions BILAG-2004 index is associated with new damage. BILAG-2004 LDA and BST persistent LDA can be considered as treatment targets. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

27. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment

Author

Perez-Sanchez, Carlos, Ruiz-Limon, Patricia, Aguirre, Maria Angeles, Bertolaccini, Maria Laura, Khamashta, Munther A., Rodriguez-Ariza, Antonio, Segui, Pedro, Collantes-Estevez, Eduardo, Barbarroja, Nuria, Khraiwesh, Husam, Gonzalez-Reyes, Jose Antonio, Villalba, Jose Manuel, Velasco, Francisco, Cuadrado, Maria Jose, and Lopez-Pedrera, Chary

Published
2012
Full Text
View/download PDF

32. The frequency and outcome of lupus nephritis: results from an international inception cohort study

Author

Hanly, John G., O’Keeffe, Aidan G., Su, Li, Urowitz, Murray B., Romero-Diaz, Juanita, Gordon, Caroline, Bae, Sang-Cheol, Bernatsky, Sasha, Clarke, Ann E., Wallace, Daniel J., Merrill, Joan T., Isenberg, David A., Rahman, Anisur, Ginzler, Ellen M., Fortin, Paul, Gladman, Dafna D., Sanchez-Guerrero, Jorge, Petri, Michelle, Bruce, Ian N., Dooley, Mary Anne, Ramsey-Goldman, Rosalind, Aranow, Cynthia, Alarcón, Graciela S., Fessler, Barri J., Steinsson, Kristjan, Nived, Ola, Sturfelt, Gunnar K., Manzi, Susan, Khamashta, Munther A., van Vollenhoven, Ronald F., Zoma, Asad A., Ramos-Casals, Manuel, Ruiz-Irastorza, Guillermo, Lim, S. Sam, Stoll, Thomas, Inanc, Murat, Kalunian, Kenneth C., Kamen, Diane L., Maddison, Peter, Peschken, Christine A., Jacobsen, Soren, Askanase, Anca, Theriault, Chris, Thompson, Kara, and Farewell, Vernon

Published
2016
Full Text
View/download PDF

33. Literature review of lupus nephritis From the Arabian Gulf region.

Author

Al-Shujairi, Arwa, Elbadawi, Faisal, Al-Saleh, Jamal, Hamouda, Mohamed, Vasylyev, Averyan, and Khamashta, Munther

Subjects
LUPUS nephritis, LITERATURE reviews, KIDNEY diseases, RENAL biopsy, MYCOPHENOLIC acid, TREATMENT effectiveness
Abstract

Introduction: The severity of lupus nephritis (LN) varies between different ethnicities. However, there are limited data regarding disease severity for LN in patients from the Arabian Gulf region; moreover, there are no treatment guidelines developed specifically for this population. The objective of this review was to characterise the incidence of LN, current treatment practices, the severity of LN, and the pathophysiology and biomarkers associated with LN in the Arabian Gulf region. Methods: A literature search using EMBASE was conducted in October, 2021 to identify publications reporting on the incidence, treatment practices, severity, pathophysiology or biomarkers associated with LN, from countries in the Arabian Gulf region (including Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and the United Arab Emirates). Additional relevant publications were provided by collaborators. A manual review of the publications was conducted to determine their relevance and data on the outcomes of interest were extracted. Results: Of 3705 publications, 54 publications were identified as relevant. LN is one of the most commonly diagnosed renal diseases within the Arabian Gulf and approximately 10%–36% of all renal biopsies are for LN. Treatment patterns within the region appear to vary and generally follow treatment guidelines recommended by the Asia Pacific League of Associations for Rheumatology (APLAR), the European Alliance of Associations for Rheumatology (EULAR) and Kidney Disease Improving Global Outcomes (KDIGO). The majority of patients receive cyclophosphamide for induction therapy, whilst others receive mycophenolate mofetil. Most studies showed that the most frequently diagnosed class of LN within the Arabian Gulf region was Class IV (up to 63% of patients with LN). Sustained or increased levels of serum creatinine and proteinuria; and depressed levels of complement C3/C4 were commonly seen among patients with LN from the Arabian Gulf region. Conclusions: This review identified that LN may manifest more severely among patients from the Arabian Gulf region than in other populations, such as Caucasian populations. A greater understanding of LN and the treatment practices within the region, as well as the development of more specific treatment guidelines for this population may help improve outcomes for patients with LN in the Arabian Gulf region. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

34. Exploring patient's experience and unmet needs on pregnancy and family planning in rare and complex connective tissue diseases: a narrative medicine approach.

Author

Marinello, Diana, Zucchi, Dina, Palla, Ilaria, Aguilera, Silvia, Galetti, Ilaria, Holmner, Monica, Sandulescu, Silvia, Scarle, Lucy, Tremarias, Dalila, Bouillot, Coralie, Cattaneo, Laura, Gaglioti, Andrea, Ticciati, Simone, Brucato, Antonio, Khamashta, Munther, Shoenfeld, Yehuda, Tincani, Angela, Talarico, Rosaria, Tani, Chiara, and Mosca, Marta

Published
2022
Full Text
View/download PDF

38. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort

Author

Parker, Ben, Urowitz, Murray B, Gladman, Dafna D, Lunt, Mark, Donn, Rachelle, Bae, Sang-Cheol, Sanchez-Guerrero, Jorge, Romero-Diaz, Juanita, Gordon, Caroline, Wallace, Daniel J, Clarke, Ann E, Bernatsky, Sasha, Ginzler, Ellen M, Isenberg, David A, Rahman, Anisur, Merrill, Joan T, Alarcón, Graciela S, Fessler, Barri J, Fortin, Paul R, Hanly, John G, Petri, Michelle, Steinsson, Kristjan, Dooley, Mary Anne, Manzi, Susan, Khamashta, Munther A, Ramsey-Goldman, Rosalind, Zoma, Asad A, Sturfelt, Gunnar K, Nived, Ola, Aranow, Cynthia, Mackay, Meggan, Ramos-Casals, Manuel, van Vollenhoven, Ronald F, Kalunian, Kenneth C, Ruiz-Irastorza, Guillermo, Lim, S Sam, Kamen, Diane L, Peschken, Christine A, Inanc, Murat, and Bruce, Ian N

Published
2015
Full Text
View/download PDF

39. Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment

Author

Ruiz-Limon, Patricia, Barbarroja, Nuria, Perez-Sanchez, Carlos, Aguirre, Maria Angeles, Bertolaccini, Maria Laura, Khamashta, Munther A, Rodriguez-Ariza, Antonio, Almadén, Yolanda, Segui, Pedro, Khraiwesh, Husam, Gonzalez-Reyes, Jose Antonio, Villalba, Jose Manuel, Collantes-Estevez, Eduardo, Cuadrado, Maria Jose, and Lopez-Pedrera, Chary

Published
2015
Full Text
View/download PDF

40. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus

Author

Perez-Sanchez, Carlos, Barbarroja, Nuria, Messineo, Sebastiano, Ruiz-Limon, Patricia, Rodriguez-Ariza, Antonio, Jimenez-Gomez, Yolanda, Khamashta, Munther A, Collantes-Estevez, Eduardo, Cuadrado, M Jose, Aguirre, M Angeles, and Lopez-Pedrera, Chary

Published
2015
Full Text
View/download PDF

41. Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

Author

Hanly, John G., Su, Li, Urowitz, Murray B., Romero-Diaz, Juanita, Gordon, Caroline, Bae, Sang-Cheol, Bernatsky, Sasha, Clarke, Ann E., Wallace, Daniel J., Merrill, Joan T., Isenberg, David A., Rahman, Anisur, Ginzler, Ellen M., Petri, Michelle, Bruce, Ian N., Dooley, M. A., Fortin, Paul, Gladman, Dafna D., Sanchez-Guerrero, Jorge, Steinsson, Kristjan, Ramsey-Goldman, Rosalind, Khamashta, Munther A., Aranow, Cynthia, Alarcón, Graciela S., Fessler, Barri J., Manzi, Susan, Nived, Ola, Sturfelt, Gunnar K., Zoma, Asad A., van Vollenhoven, Ronald F., Ramos-Casals, Manuel, Ruiz-Irastorza, Guillermo, Lim, Sam S., Kalunian, Kenneth C., Inanc, Murat, Kamen, Diane L., Peschken, Christine A., Jacobsen, Soren, Askanase, Anca, Theriault, Chris, Thompson, Kara, and Farewell, Vernon

Published
2015
Full Text
View/download PDF

46. The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients.

Author

Yee, Chee-Seng, Khamashta, Munther, Akil, Mohammed, Kilding, Rachael, Giles, Ian, Williams, David, Bruce, Ian N, and Gordon, Caroline

Subjects
SYSTEMIC lupus erythematosus, PREGNANCY outcomes, CROSS-sectional method
Abstract

Objectives This study was to determine whether the BILAG2004-Pregnancy Index (BILAG2004-P) has construct/criterion validity and is sensitive to change. Methods This was an observational multicentre study that recruited pregnant SLE patients. Data were collected on disease activity [using the BILAG2004-P and Physician Global Assessment (PGA)], investigations and therapy at each assessment. The overall BILAG2004-P score as determined by the highest score achieved by any system was used in the analysis. Cross-sectional analysis was used for construct and criterion validity. The comparison was with C3, C4 and anti-dsDNA for construct validity, while it was with change in therapy and PGA in criterion validity. Sensitivity to change was assessed by determining the relationship between the change in BILAG2004-P and the change in therapy between two consecutive visits. Results A total of 97 patients with 112 pregnancies were recruited. There were 610 assessments available for construct/criterion validity analysis (98.2% of pregnancies had more than one assessment) and 497 observations for sensitivity to change analysis. Increasing BILAG2004-P scores were associated with low C3. The active BILAG2004-P score (grade A or B) was associated with an increase in therapy and the PGA of active disease. There was an increasing likelihood of higher overall scores with an increase in therapy and the PGA of active disease. In the sensitivity to change analysis, an increase in the BILAG2004-P score was associated with an increase in therapy and inversely associated with a decrease in therapy. A decrease in the BILAG2004-P score was associated with a decrease in therapy and inversely associated with an increase in therapy. Conclusion The BILAG2004-P has criterion validity and is sensitive to change. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results